NEW YORK (GenomeWeb) – Israeli biotech firm Can-Fite BioPharma announced today an agreement with Smart Assays to develop a biomarker blood test kits for the A3 adenosine receptor (A3AR).

Molecular biology labs would be able to use Can-Fite's A3AR biomarker kit to identify a patient's response to the firm's drugs. A3AR is present in high concentrations in inflammatory cells and cancer cells, and Can-Fite's drugs target and bind to A3AR, causing cell apoptosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.